
Opinion|Videos|November 26, 2025
Key Objectives and Data from ASCENT-04
This segment explains how ASCENT-04 assessed whether moving sacituzumab govitecan into the first-line setting with immunotherapy could improve outcomes for a population with historically limited options.
Advertisement
Episodes in this series

The ASCENT-04/KN-D19 study evaluated the efficacy of sacituzumab govitecan (SG) combined with pembrolizumab versus standard chemotherapy plus pembrolizumab in first-line treatment of metastatic TNBC. The study addressed a critical unmet need: improving outcomes in a population with historically limited options. SG has demonstrated benefit in the second-line setting, and combining it with immunotherapy upfront aimed to enhance clinical responses.
Advertisement
Advertisement
Advertisement
Trending on Pharmacy Times
1
FDA Fast Tracks First-in-Class TNFR2 Antibody as Chemotherapy-Free Strategy for Platinum-Resistant Ovarian Cancer
2
The Inflation Reduction Act and Oncology Drug Pricing: What Pharmacists Need to Know
3
Beat the Heat: 10 Common Medication Culprits Causing Heat Intolerance
4
Yes, COVID-19 Is Still a Big Deal. Pharmacy Is the Tip of the Spear (and Needle)
5


































































































